ACRS צמיחת רווח נקי למניה משנה לשנה ב-12 החודשים האחרונים Aclaris

Aclaris Therapeutics (ACRS) relies on exclusive patents that enable the company to maintain significant pricing power for its dermatology treatments. However, geopolitics create risks of raw material supply disruptions from Asia. Meanwhile, its independence from macroeconomic trends gives the asset defensive qualities. The quarterly earnings per share history on GURU.Markets illustrates a trend where -3.80 serves as the base parameter value.
ACRS (Aclaris Therapeutics): פילוחים אנליטיים ודוחות לפי אינדיקטורים

When assessing the resilience of Aclaris Therapeutics (ACRS) to market downturns, it is essential to consider the specifics of drug development for dermatology and immunology. The company's scientific potential temporarily offsets pricing competition during the clinical trial period. The quarterly EPS history clearly demonstrates the percentage dynamics of net profit per share. The current value of -3.80 allows for an objective measurement of real business efficiency. This indicator serves as a reliable filter against unjustified investments at valuation peaks.